The growth-hormone secretagogue class is one of the most frequently referenced groups in the research peptide literature, and also one of the most commonly confused. This explainer compares the four most-referenced compounds in the class as they appear in published research. It contains no dosing or human-use guidance.
What “Secretagogue” Means
A secretagogue is a compound that, in research models, is associated with stimulating the release of another substance. In this class, the literature describes compounds investigated in relation to the growth-hormone axis. The four most-referenced members are CJC-1295, Ipamorelin, Sermorelin, and Tesamorelin. They are related but mechanistically distinct.
CJC-1295
CJC-1295 is described in the literature as a growth-hormone-releasing hormone analog. Research references two forms: one with a Drug Affinity Complex (DAC) and one without. The literature describes the DAC version as longer-acting and the non-DAC version as shorter-acting. CJC-1295 is frequently co-investigated alongside Ipamorelin in published protocols, which is why the two appear together in the catalog 2X Blend.
Ipamorelin
Ipamorelin is described in the literature as a selective growth-hormone secretagogue. The published work most often emphasizes its selectivity, meaning research describes it as acting on a specific pathway with limited reported activity elsewhere. Its frequent pairing with CJC-1295 in the literature reflects an interest in combining a releasing-hormone analog with a selective secretagogue in research models.
Sermorelin
Sermorelin is one of the earliest growth-hormone-releasing hormone fragments in the research record. It is described in the literature as a shorter-chain analog and is frequently referenced as a foundational compound in growth-axis research. It is often discussed as a comparison point against the newer analogs in the class.
Tesamorelin
Tesamorelin is a growth-hormone-releasing hormone analog with a particularly deep research record. In published literature it is most often associated with visceral adipose tissue research models. It carries an FDA-approved analog status in a specific clinical context, which makes it a frequent reference point in the literature, though SYNGEN sells it strictly as a research compound.
How They Differ At A Glance
- CJC-1295 — releasing-hormone analog, short or long-acting depending on DAC.
- Ipamorelin — selective secretagogue, frequently paired with CJC-1295.
- Sermorelin — early releasing-hormone fragment, foundational reference compound.
- Tesamorelin — releasing-hormone analog with a deep visceral-research literature.
Where The Class Sits In The Catalog
These compounds form the core of the Growth category and appear across several curated research groupings, including the Alpha Performance and Body Recomp reference stacks. Each grouping reflects combinations investigated together in published literature and is provided as reference only for qualified researchers.